Clinical Trial Update: 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period [Phase 3]

View source ↗

Summary

A Phase 3 study comparing saxagliptin added to metformin with a sulphonylurea as add-ons, followed by a 52-week extension; the trial has completed and results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin (saxagliptin)
• Sulphonylurea (sulphonylurea)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2010-09-06